GFM
NRIX icon

GF Fund Management’s Nurix Therapeutics NRIX Stock Holding History

GF Fund Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.9K Sell
2,180
-86
-4% -$1.47K ﹤0.01% 383
2026
Q1 		$35.1K Buy
2,266
+274
+14% +$4.54K ﹤0.01% 441
2025
Q4 		$37.8K Buy
1,992
+347
+21% +$4.99K ﹤0.01% 432
2025
Q3 		$15.2K Sell
1,645
-169
-9% -$1.75K ﹤0.01% 522
2025
Q2 		$20.7K Hold
1,814
– – ﹤0.01% 498
2025
Q1 		$21.6K Buy
1,814
+327
+22% +$5.47K ﹤0.01% 496
2024
Q4 		$28K Buy
+1,487
New +$34.1K ﹤0.01% 440

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GF Fund Management's NRIX Position: Q2 2026 in Review

GF Fund Management reduced its Nurix Therapeutics (NRIX) stake by 3.8% in Q2 2026, selling an estimated $1.47K and leaving 2,180 shares worth $52.9K. The position accounts for ﹤0.01% of the portfolio, ranked #383.

GF Fund Management first reported a position in NRIX in Q4 2024 and has held it in 7 quarters since. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • GF Fund Management held 2,180 shares of Nurix Therapeutics worth $52.9K as of Q2 2026.
  • GF Fund Management sold 86 Nurix Therapeutics shares in Q2 2026, an estimated $1.47K.
  • Nurix Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #383 holding.
  • GF Fund Management first reported a position in Nurix Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.